Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REV1 | Q9UBZ9 | 1/20 | 0.76 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.66 |
| ▸ | ABCB1 | P08183 | 9/20 | 0.60 |
| ▸ | ABCC1 | P33527 | 3/20 | 0.60 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.53 |
| ▸ | HTR1A | P08908 | 1/20 | 0.53 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.53 |
| ▸ | DRD4 | P21917 | 1/20 | 0.53 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.53 |
| ▸ | HTR2C | P28335 | 1/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.53 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.53 |
| ▸ | DRD3 | P35462 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3059849 | 0.92 | REV1 (0.74) | REV1CHRNA7ABCB1ABCC1ABCG2 | |
| SCHEMBL3050371 | 0.92 | REV1 (0.84) | REV1CHRNA7ABCB1ABCC1ABCG2 | |
| SCHEMBL3059193 | 0.91 | REV1 (0.87) | REV1CHRNA7ABCB1ABCC1ABCG2 | |
| SCHEMBL3062442 | 0.89 | REV1 (0.72) | REV1CHRNA7ABCB1ABCC1ABCG2 | |
| SCHEMBL3055739 | 0.88 | REV1 (0.72) | REV1CHRNA7ABCB1ABCC1ABCG2 | |
| SCHEMBL3059243 | 0.88 | REV1 (0.78) | REV1CHRNA7ABCB1ABCC1ABCG2 | |
| SCHEMBL3055433 | 0.87 | REV1 (0.70) | REV1CHRNA7ABCB1ABCC1ABCG2 | |
| SCHEMBL3668878 | 0.86 | REV1 (0.66) | REV1CHRNA7ABCB1ABCC1ABCG2 | |
| SCHEMBL3064267 | 0.86 | REV1 (0.72) | REV1CHRNA7ABCB1ABCC1ABCG2 | |
| SCHEMBL3046416 | 0.86 | REV1 (0.71) | REV1CHRNA7ABCB1ABCC1ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222299-A1 | COMPOUND | STERIX LIMITED (GB) | 2010-09-02 | — | — | US | claimed |
| US-9133145-B2 | Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme | ABBVIE INC. (US) | 2015-09-15 | — | — | US | disclosed |
| EP-1751108-B1 | ADAMANTYL-ACETAMIDE DERIVATIVES AS INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBVIE INC (US) | 2014-07-30 | — | — | EP | disclosed |
| US-20130338169-A1 | METHODS OF USE OF INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBVIE INC. (US) | 2013-12-19 | — | — | US | disclosed |
| US-8415354-B2 | Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme | ABBOTT LABORATORIES (US) | 2013-04-09 | — | — | US | disclosed |
| US-8394825-B2 | Compound | STERIX LIMITED (GB) | 2013-03-12 | — | — | US | disclosed |
| US-8372841-B2 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme | ABBOTT LABORATORIES (US) | 2013-02-12 | — | — | US | disclosed |
| US-20100222316-A1 | INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBOTT LABORATORIES (US) | 2010-09-02 | — | — | US | disclosed |
| US-20100222299-A1 | COMPOUND | STERIX LIMITED (GB) | 2010-09-02 | — | — | US | disclosed |
| US-20090192141-A1 | METHODS OF USE OF INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBOTT LABORATORIES (US) | 2009-07-30 | — | — | US | disclosed |
| US-20050277647-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme | ABBVIE INC. | 2005-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222316-A1 | INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | HSD11B1, HSD17B1, HSD11B2 | REV1 639/4885CHRNA7 3949/4885ABCB1 1572/4885 |
| US-20130338169-A1 | METHODS OF USE OF INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | HSD11B1, HSD17B1, HSD11B2 | REV1 860/4885CHRNA7 1688/4885ABCB1 2037/4885 |
| US-20090192141-A1 | METHODS OF USE OF INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | HSD11B1, HSD17B1, HSD11B2 | REV1 860/4885CHRNA7 1688/4885ABCB1 2037/4885 |
| US-20050277647-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme | HSD11B1, HSD17B1, HSD11B2 | REV1 639/4885CHRNA7 3949/4885ABCB1 1572/4885 |
| US-20100222299-A1 | COMPOUND | MKI67, VHL, MYC | REV1 1520/4885CHRNA7 4760/4885ABCB1 754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.